Search results for " cancer patients"

showing 10 items of 31 documents

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: The use of fixed sub-therap…

2012

No data are available regarding the management of cancer patients requiring interruption of long-term vitamin-K antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of low-molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at fixed subtherapeutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated 12 hr after surgery and VKA the day after. In patients receiving chem…

AdultMaleRiskmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLow molecular weight heparinAntineoplastic AgentsHemorrhagelow-molecular weight heparin (LMWH); long-term vitamin-K antagonist (VKA) therapy; cancer patientsSettore MED/15 - Malattie Del SanguePostoperative ComplicationsNeoplasmsThromboembolismAtrial FibrillationHumansThrombophiliaMedicinecancer thrombocytopenia low molecular weight heparinProspective StudiesProspective cohort studyAgedAged 80 and overChemotherapybusiness.industryIncidenceWarfarinAnticoagulantsCancerHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaThrombosisSurgeryClinical trialHeart Valve ProsthesisAnesthesialow-molecular weight heparin (LMWH)FemaleWarfarinlong-term vitamin-K antagonist (VKA) therapycancer patientsbusinessmedicine.drugAmerican Journal of Hematology
researchProduct

A Prospective Randomized Study of Corticosteroids as Adjuvant Drugs to Opioids in Advanced Cancer Patients

2007

This randomized controlled study evaluated the role of corticosteroids as adjuvants to opioid therapy in 76 advanced cancer patients with pain who requiring strong opioids. Patients were divided in 2 groups. Group O received conventional opioid treatment. Group OS received dexamethasone (8 mg orally) along with conventional treatment. Pain and symptom intensity, sense of well-being, and opioid escalation index and distress score were recorded at weekly intervals until death. No differences in pain intensity, opioid consumption, and opioid escalation index were found in 66 patients who survived 33 to 37 days. Corticosteroids did not provide significant additional analgesia to opioids, but p…

AdultMalecorticosteroidmedicine.medical_treatmentAnti-Inflammatory Agentslaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trial030502 gerontologylawNeoplasmsmedicineHumansProspective Studiesopioids in advanced cancer patientsprospective randomized studyProspective cohort studyDexamethasoneAgedPain MeasurementAged 80 and overAnalysis of VarianceChemotherapyadjuvant drugDose-Response Relationship Drugbusiness.industryPalliative CareGeneral MedicineMiddle AgedPain IntractableAnalgesics OpioidTreatment OutcomeOpioidChemotherapy Adjuvant030220 oncology & carcinogenesisAnesthesiaDrug Therapy CombinationFemale0305 other medical scienceCancer painbusinessAdjuvantFollow-Up Studiesmedicine.drugAmerican Journal of Hospice and Palliative Medicine®
researchProduct

Patients' and relatives' perceptions about intravenous and subcutaneous hydration.

2005

Hydration during palliative care is a controversial topic. Most of the arguments are based on anedoctal reports that have not been substantiated with scientific data. Given that the choice is problematic from a clinical perspective, preferences of patients and family should dictate whether intravenous fluids are administered. The aim of this study was to evaluate patient and family perceptions about hydration and two modes of providing hydration. Fifty-four consecutive patients admitted to an acute pain relief and palliative care unit who required hydration completed a questionnaire regarding their perceptions on hydration and modes of hydration. Similarly, the principal family carer was ch…

AdultMalemedicine.medical_specialtyPalliative carePatientsmedia_common.quotation_subjectInjections SubcutaneousMEDLINEadvanced cancer patientsPatient satisfactionPerceptionmedicineSubcutaneous HydrationHumansFamilyIntensive care medicineFamily carerInfusions Intravenousintravenous and subcutaneous hydrationGeneral Nursingmedia_commonAgedAged 80 and overbusiness.industryPalliative CareMiddle AgedSubcutaneous routeAnesthesiology and Pain MedicinePatient SatisfactionPatients' and relatives' perceptionFluid TherapyFemaleNeurology (clinical)businessIntravenous routeJournal of pain and symptom management
researchProduct

Pattern and characteristics of advanced cancer patients admitted to hospices in Italy

2013

Abstract The aim of this multicenter study was to assess the pattern and the characteristics of advanced cancer patients admitted to hospices. A consecutive sample of patients admitted in a period of 6 months was taken into consideration. Two hundred thirty-six patients admitted to hospices were consecutively assessed. Ninety-six percent of patients were admitted in acute hospital in the previous 3 months, with a mean time spent in hospital of 34.5 days, and 47 % of patients had received chemotherapy the month before hospice admission. Thirty-four percent of patients for whom data were available had significant persistent pain, and 44 % of them presented episodes of breakthrough pain. Sixty…

AdultMalemedicine.medical_specialtyPalliative caredescriptive studyPain medicineSettore MED/42 - Igiene Generale E ApplicataFentanyladvanced cancer patientNeoplasmsOutcome Assessment Health CaremedicineHumansProspective StudiesIntensive care medicineProspective cohort studySurvival analysisAgedadvanced cancer patients; hospice; descriptive studyAged 80 and overTerminal CareMarital Statusbusiness.industryNursing researchPalliative CareHospicesLength of StayMiddle AgedSurvival AnalysisAnalgesics OpioidLogistic ModelsOncologyOpioidItalyhospiceEmergency medicineMarital statusFemalebusinessmedicine.drug
researchProduct

Changes in microflora in dental plaque from cancer patients undergoing chemotherapy and the relationship of these changes with mucositis: a pilot stu…

2015

Background: To assess changes in oral microflora in dental plaque from cancer patients within 7 days of the first course of chemotherapy, and the relationship of the changes with mucositis. Material and Methods: Thirty cancer patients, divided into a test group undergoing chemotherapy and a control group no undergoing chemotherapy, were enrolled in this pilot study. Oral microflora were cultured from three samples of dental plaque at t0 (before chemotherapy), t1 (1 day after chemotherapy) and t2 (7 days after chemotherapy). Single and crossed descriptive analyses were used to establish prevalence, and the χ 2 test was used to establish the statistical significance of the differences observe…

AdultMalemedicine.medical_specialtyTime Factorsdental plaquemedicine.medical_treatmentDentistryAntineoplastic AgentsPilot ProjectsOdontologíaDental plaquechemotherapyoral microflorastomatognathic systemNeoplasmsStatistical significanceInternal medicinemedicineMucositisHumansGeneral DentistryStomatitisStomatitisChemotherapyOral Medicine and PathologyBacteriabiologybusiness.industryResearchCancerMiddle Agedmedicine.diseasebiology.organism_classification:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludBacterial Loadoral microflora; dental plaque; cancer patients; chemotherapystomatognathic diseasesCross-Sectional StudiesOtorhinolaryngologyActinobacillusUNESCO::CIENCIAS MÉDICASFemaleSurgeryFusobacterium nucleatumbusinesscancer patients
researchProduct

Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study

2014

Purpose We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. Patients and Methods Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to discontinue it (group A2), and patients without RVT stopped LMWH (group B). The primary end point was recurrent venous thromboembolism (VTE) during the 1 year after disconinuation of LMWH, and the secondar…

Cancer Researchmedicine.medical_specialtymedicine.drug_classDeep veinPopulationLow molecular weight heparinSettore MED/42 - Igiene Generale E ApplicataGroup BSettore MED/15 - Malattie Del SangueInternal medicineresidual vein thrombosis low molecular weight heparin cancer patientsmedicineeducationFirst episodeeducation.field_of_studybusiness.industrylow molecular weight heparinHazard ratioantivitamin K; low molecular weight heparin; nadroparinCancermedicine.diseaseThrombosisSurgerymedicine.anatomical_structureOncologynadroparinantivitamin Kbusiness
researchProduct

Cephalosporin resistant Escherichia coli from cancer patients in Cairo, Egypt.

2013

Cephalosporin-resistant Escherichia coli has been increasingly reported worldwide. In this study, 32 cephalosporin resistant E. coli isolates identified from cancer patients in Cairo, Egypt in 2009-2010 were analyzed. Twenty-three were of phylogenetic group D, seven A and one each B1 and B2. By rep-PCR 15 phylogroup D isolates were grouped in four clusters, one with sequence type (ST) 405 and three ST68. Seventeen isolates showed single patterns. blaCTX-M-15 and aac(6')-Ib-cr were the most common resistance determinants. blaOXA-48 and blaVIM were also detected. Multidrug resistant E. coli seriously affects healthcare, especially in immunocompromised hosts, such as cancer patients.

Escherichia coli multiresistance cancer patientsSettore MED/42 - Igiene Generale E Applicata
researchProduct

Does pain intensity predict a poor opioid response in cancer patients?

2011

Abstract Aim The aim of this study was to test the hypothesis that initial pain intensity is not a predictive factor of poor opioid response in advanced cancer patients, as suggested by a recent work. Methods A secondary analysis of one-hundred-sixty-seven patients referred for treatment of cancer-related pain was conducted. Pain intensity at admission was recorded and patients were divided in three categories of pain intensity: mild, moderate and severe. Patients were offered a treatment with opioid dose titration, according to department policy. Data regarding opioid doses and pain intensity were collected after dose titration was completed. Four levels of opioid response were considered:…

MaleCancer ResearchOpioid responseopioid response in cancer patientPainOpioidSettore MED/42 - Igiene Generale E ApplicataSecondary analysisNeoplasmsmedicineHumansProspective StudiesCancer painKarnofsky Performance StatusAdverse effectAgedPain Measurementpain intensityAnalgesicsAnalysis of VarianceAssessment tools; Cancer pain; Opioid response; Aged; Analgesics Opioid; Analysis of Variance; Female; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Prospective Studies; Treatment Outcome; Cancer Research; Oncologybusiness.industryCancerMiddle Agedmedicine.diseaseAdvanced cancerIntensity (physics)Predictive factorAnalgesics OpioidAssessment toolsTreatment OutcomeOncologyOpioidAnesthesiapain intensity; opioid response in cancer patients; trial clinicoFemaletrial clinicoCancer painbusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?

2006

Abstract Background While opioids in increasing doses may produce adverse effects, the same adverse effects may be associated with poor pain control. Moreover, in the clinical setting symptomatic treatment and illness may balance the outcome of opioid titration. Some adverse effects may tend to disappear continuing the treatment in a long-term period. Aims The aim of this study was to monitor the effects of a rapid opioid titration combined with symptomatic treatment in patients with poor relief and to monitor these changes in the following period of 20 days. Methods A consecutive sample of 35 patients admitted to an acute Pain Relief and Palliative Care Unit were titrated with opioids, acc…

MaleWeaknessPalliative careConstipationNauseaOpioid-induced symptoms; pain relief; advanced cancer patients; longitudinal prospective studymedia_common.quotation_subjectPainpain reliefadvanced cancer patientlongitudinal prospective studyNeoplasmsmedicineHumansLongitudinal StudiesProspective StudiesAdverse effectmedia_commonbusiness.industryPalliative CareAppetiteMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineOpioidPatient SatisfactionAnesthesiaEmergency MedicineVomitingFemalemedicine.symptomCancer painbusinessOpioid-induced symptommedicine.drug
researchProduct

The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients

2012

Abstract OBJECTIVES: The aim of this study was to evaluate the opioid response in patients receiving morphine and pregabalin, independently from the presumed pain mechanisms, in comparison with patients receiving morphine treatment only. METHODS: A multicenter prospective randomized controlled study was carried out in a sample of 70 advanced cancer patients with pain requiring strong opioids. Thirty-five patients (group MO) were randomized to receive sustained-release morphine using initial doses of 60 mg/day. Thirty-five patients (group MO-PR) were randomized to start the same morphine doses and pregabalin in increasing doses, starting with 25 mg/day up to 150 mg/day in one week. The follo…

Malecancer painAnalgesicPregabalinPregabalinPainSettore MED/42 - Igiene Generale E Applicatalaw.inventionDose-Response Relationshipadvanced cancer patientDrug TherapyQuality of lifeRandomized controlled triallawassessment toolsNeoplasmsmedicineHumansDrug Interactionslow doses pregabalinBrief Pain Inventorygamma-Aminobutyric AcidPain Measurementneuropathic painAnalgesicsDose-Response Relationship DrugMorphinebusiness.industryassessment tools; cancer pain; neuropathic pain; opioid response; Analgesics; Dose-Response Relationship Drug; Drug Interactions; Drug Therapy Combination; Female; Humans; Italy; Male; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Pregabalin; Treatment Outcome; gamma-Aminobutyric Acid; Anesthesiology and Pain Medicine; Neurology (clinical)Palliative CareAdvanced cancerTreatment OutcomeAnesthesiology and Pain MedicineItalyOpioidlow doses pregabalin; advanced cancer patients; epidemiologic studyopioid responseAnesthesiaCombinationepidemiologic studyMorphineDrug Therapy CombinationFemaleNeurology (clinical)Drugbusinessmedicine.drug
researchProduct